Children's Oncology Group's 2013 Blueprint for Research: Acute Lymphoblastic Leukemia

Overview

Journal Pediatr Blood Cancer

Specialties Hematology
Oncology
Pediatrics

Date 2012 Dec 21

PMID 23255467

Citations 79

Authors

Stephen P Hunger

Mignon L Loh

James A Whitlock

Naomi J Winick

William L Carroll

Meenakshi Devidas

Elizabeth A Raetz

Affiliations

Soon will be listed here.

Abstract

Approximately 90% of the 2,000 children, adolescents, and young adults enrolled each year in Children's Oncology Group acute lymphoblastic leukemia (ALL) trials will be cured. However, high-risk subsets with significantly inferior survival remain, including infants, newly diagnosed patients with age ≥10 years, white blood count ≥50,000/µl, poor early response or T-cell ALL, and relapsed ALL patients. Effective strategies to improve survival include better risk stratification, optimizing standard chemotherapy and combining targeted therapies with cytotoxic chemotherapy, the latter of which is dependent upon identification of key driver mutations present in ALL.

Citing Articles

Value of routine blood count surveillance in detecting relapse in acute lymphoblastic leukemia.

AlHarbi S, Taha A, Ashi A, Elimam N, Althubaiti S Front Pediatr. 2025; 12():1488686.

PMID: 39834493 PMC: 11743496. DOI: 10.3389/fped.2024.1488686.

Very early remission and increased apoptosis with the use of Pentoxifylline in children with acute lymphoblastic leukemia.

Salceda-Rivera V, Ortiz-Lazareno P, Hernandez-Flores G, Vazquez-Urrutia J, Meza-Arroyo J, Pardo-Zepeda M Front Oncol. 2024; 14:1401262.

PMID: 39421449 PMC: 11484046. DOI: 10.3389/fonc.2024.1401262.

Prediction of Response to FDA-Approved Targeted Therapy and Immunotherapy in Acute Lymphoblastic Leukemia (ALL).

Khawaji Z, Khawaji N, Alahmadi M, Elmoneim A Curr Treat Options Oncol. 2024; 25(9):1163-1183.

PMID: 39102166 DOI: 10.1007/s11864-024-01237-w.

Progression of brain injuries associated with methotrexate chemotherapy in childhood acute lymphoblastic leukemia.

Bansal R, Bhojwani D, Sun B, Sawardekar S, Wayne A, Ouassil H Pediatr Res. 2024; 97(1):348-359.

PMID: 38951657 PMC: 11798858. DOI: 10.1038/s41390-024-03351-9.

Waning of Humoral Immunity to Vaccine-Preventable Diseases in Children Treated for Acute Lymphoblastic Leukemia: A Single-Center Retrospective Cross-Sectional Analysis.

Ince T, Gurocak O, Totur G, Yilmaz S, Oren H, Aydin A Turk J Haematol. 2024; 41(3):160-166.

PMID: 38801016 PMC: 11589364. DOI: 10.4274/tjh.galenos.2024.2024.0150.

References

Trevino L, Yang W, French D, Hunger S, Carroll W, Devidas M . Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet. 2009; 41(9):1001-5. PMC: 2762391. DOI: 10.1038/ng.432. View

Kamps W, van der Pal-de Bruin K, Veerman A, Fiocco M, Bierings M, Pieters R . Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. Leukemia. 2009; 24(2):309-19. DOI: 10.1038/leu.2009.258. View

Graf Einsiedel H, von Stackelberg A, Hartmann R, Fengler R, Schrappe M, Janka-Schaub G . Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87. J Clin Oncol. 2005; 23(31):7942-50. DOI: 10.1200/JCO.2005.01.1031. View

Dorge P, Meissner B, Zimmermann M, Moricke A, Schrauder A, Bouquin J . IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica. 2012; 98(3):428-32. PMC: 3659952. DOI: 10.3324/haematol.2011.056135. View

Matloub Y, Bostrom B, Hunger S, Stork L, Angiolillo A, Sather H . Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2011; 118(2):243-51. PMC: 3138679. DOI: 10.1182/blood-2010-12-322909. View

Hunger S, Lu X, Devidas M, Camitta B, Gaynon P, Winick N . Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol. 2012; 30(14):1663-9. PMC: 3383113. DOI: 10.1200/JCO.2011.37.8018. View

Kurtzberg J, Ernst T, Keating M, Gandhi V, Hodge J, Kisor D . Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol. 2005; 23(15):3396-403. DOI: 10.1200/JCO.2005.03.199. View

Pui C, Pei D, Sandlund J, Ribeiro R, Rubnitz J, Raimondi S . Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia. 2009; 24(2):371-82. PMC: 2820159. DOI: 10.1038/leu.2009.252. View

Arico M, Schrappe M, Hunger S, Carroll W, Conter V, Galimberti S . Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol. 2010; 28(31):4755-61. PMC: 3020705. DOI: 10.1200/JCO.2010.30.1325. View

10.

Roy A, Cargill A, Love S, Moorman A, Stoneham S, Lim A . Outcome after first relapse in childhood acute lymphoblastic leukaemia - lessons from the United Kingdom R2 trial. Br J Haematol. 2005; 130(1):67-75. DOI: 10.1111/j.1365-2141.2005.05572.x. View

11.

Smith M, Arthur D, Camitta B, Carroll A, Crist W, Gaynon P . Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996; 14(1):18-24. DOI: 10.1200/JCO.1996.14.1.18. View

12.

French D, Hamilton L, Mattano Jr L, Sather H, Devidas M, Nachman J . A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008; 111(9):4496-9. PMC: 2343589. DOI: 10.1182/blood-2007-11-123885. View

13.

Nguyen K, Devidas M, Cheng S, La M, Raetz E, Carroll W . Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia. 2008; 22(12):2142-50. PMC: 2872117. DOI: 10.1038/leu.2008.251. View

14.

Maude S, Tasian S, Vincent T, Hall J, Sheen C, Roberts K . Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood. 2012; 120(17):3510-8. PMC: 3482861. DOI: 10.1182/blood-2012-03-415448. View

15.

Nachman J, Heerema N, Sather H, Camitta B, Forestier E, Harrison C . Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood. 2007; 110(4):1112-5. PMC: 1939895. DOI: 10.1182/blood-2006-07-038299. View

16.

Borowitz M, Devidas M, Hunger S, Bowman W, Carroll A, Carroll W . Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood. 2008; 111(12):5477-85. PMC: 2424148. DOI: 10.1182/blood-2008-01-132837. View

17.

Messinger Y, Gaynon P, Raetz E, Hutchinson R, Dubois S, Glade-Bender J . Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer. 2010; 55(2):254-9. DOI: 10.1002/pbc.22456. View

18.

Hertzberg L, Vendramini E, Ganmore I, Cazzaniga G, Schmitz M, Chalker J . Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood. 2009; 115(5):1006-17. DOI: 10.1182/blood-2009-08-235408. View

19.

Mitchell C, Richards S, Harrison C, Eden T . Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001. Leukemia. 2009; 24(2):406-18. PMC: 2820452. DOI: 10.1038/leu.2009.256. View

20.

Mullighan C, Phillips L, Su X, Ma J, Miller C, Shurtleff S . Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science. 2008; 322(5906):1377-80. PMC: 2746051. DOI: 10.1126/science.1164266. View